Helicos BioSciences last week disclosed how much of the proceeds from its planned initial public offering would go towards R&D; marketing, sales, and service; and manufacturing of its upcoming HeliScope sequencing system.
The company also said it believes the net proceeds from the offering, together with its existing resources, will be enough to meet its cash needs through the end of 2008.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.